Eighty-five percent of lung cancers are non-small cell lung cancers (NSCLC) [38], with metastasis and ABC transporter-driven chemotherapeutic resistance as common features of these cancers either at the time of diagnosis or manifesting during the treatment process [39–44]. Here, ABCG2 is linked to non-small cell lung carcinoma.